Etoricoxib Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 60 mg, 90 mg, 120 mg
Reference Brands: Arcoxia (EU)
Category:
Arthritis
Etoricoxib selectively inhibits the COX-2 enzyme, reducing prostaglandin synthesis responsible for pain and inflammation. It provides effective relief in rheumatoid arthritis and osteoarthritis, with a lower risk of gastrointestinal side effects compared to non-selective NSAIDs. Benefits include rapid pain reduction, improved mobility, and better safety profile for long-term use.
Etoricoxib tablets is available in Tablets
and strengths such as 60 mg, 90 mg, 120 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Etoricoxib tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Etoricoxib tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Etoricoxib tablets are approved in the EU for managing rheumatoid arthritis, osteoarthritis, and gout. In the EU, brands like Arcoxia are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, etoricoxib is not approved by the FDA but is marketed in certain countries outside the US. Both regions require comprehensive dossiers for initial approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for etoricoxib tablets, ensuring adherence to European standards for safe, effective pain and inflammation management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing